Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease

[1]  M. Dubinsky,et al.  Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials , 2022, The Lancet.

[2]  M. Dubinsky,et al.  Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial , 2022, The Lancet.

[3]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[4]  M. Neurath,et al.  Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? , 2020, Frontiers in Medicine.

[5]  L. Peyrin-Biroulet,et al.  Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach , 2020, Expert review of gastroenterology & hepatology.

[6]  J. Gisbert,et al.  Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice. , 2019, Journal of Crohn's & colitis.

[7]  P. Rutgeerts,et al.  Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. , 2018, Gastroenterology.

[8]  M. Regueiro,et al.  ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.

[9]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[10]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[11]  J. Gisbert,et al.  Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed , 2015, Alimentary pharmacology & therapeutics.

[12]  P. Kawalec,et al.  Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis , 2013, Archives of medical science : AMS.

[13]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  P. Moayyedi,et al.  Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[15]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.